Literature DB >> 15894267

Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice.

Sunil R Hingorani1, Lifu Wang, Asha S Multani, Chelsea Combs, Therese B Deramaudt, Ralph H Hruban, Anil K Rustgi, Sandy Chang, David A Tuveson.   

Abstract

To define the genetic requirements for pancreatic ductal adenocarcinoma (PDA), we have targeted concomitant endogenous expression of Trp53(R172H) and Kras(G12D) to the mouse pancreas, revealing the cooperative development of invasive and widely metastatic carcinoma that recapitulates the human disease. The primary carcinomas and metastases demonstrate a high degree of genomic instability manifested by nonreciprocal translocations without obvious telomere erosion-hallmarks of human carcinomas not typically observed in mice. No mutations were discovered in other cardinal tumor suppressor gene pathways, which, together with previous results, suggests that there are distinct genetic pathways to PDA with different biological behaviors. These findings have clear implications for understanding mechanisms of disease pathogenesis, and for the development of detection and targeted treatment strategies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15894267     DOI: 10.1016/j.ccr.2005.04.023

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  1099 in total

Review 1.  Genetically Engineered Mouse Models of K-Ras-Driven Lung and Pancreatic Tumors: Validation of Therapeutic Targets.

Authors:  Matthias Drosten; Carmen Guerra; Mariano Barbacid
Journal:  Cold Spring Harb Perspect Med       Date:  2018-05-01       Impact factor: 6.915

2.  Aberrant signaling pathways in pancreatic cancer: a two compartment view.

Authors:  Angela L McCleary-Wheeler; Robert McWilliams; Martin E Fernandez-Zapico
Journal:  Mol Carcinog       Date:  2012-01       Impact factor: 4.784

3.  The ARF tumor suppressor inhibits tumor cell colonization independent of p53 in a novel mouse model of pancreatic ductal adenocarcinoma metastasis.

Authors:  Viviane Palhares Muniz; J Matthew Barnes; Seema Paliwal; Xuefeng Zhang; Xiaoyun Tang; Songhai Chen; Kokou D Zamba; Joseph J Cullen; David K Meyerholz; Shari Meyers; J Nathan Davis; Steven R Grossman; Michael D Henry; Dawn E Quelle
Journal:  Mol Cancer Res       Date:  2011-06-02       Impact factor: 5.852

4.  Development of an orthotopic model of invasive pancreatic cancer in an immunocompetent murine host.

Authors:  William W Tseng; Daniel Winer; Justin A Kenkel; Okmi Choi; Alan H Shain; Jonathan R Pollack; Randy French; Andrew M Lowy; Edgar G Engleman
Journal:  Clin Cancer Res       Date:  2010-06-09       Impact factor: 12.531

Review 5.  Re-adapting T cells for cancer therapy: from mouse models to clinical trials.

Authors:  Ingunn M Stromnes; Thomas M Schmitt; Aude G Chapuis; Sunil R Hingorani; Philip D Greenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

6.  A novel terpenoid class for prevention and treatment of KRAS-driven cancers: Comprehensive analysis using in situ, in vitro, and in vivo model systems.

Authors:  Arsheed A Ganaie; Hifzur R Siddique; Ishfaq A Sheikh; Aijaz Parray; Lei Wang; Jayanth Panyam; Peter W Villalta; Yibin Deng; Badrinath R Konety; Mohammad Saleem
Journal:  Mol Carcinog       Date:  2020-04-15       Impact factor: 4.784

7.  Selective inhibition of pancreatic ductal adenocarcinoma cell growth by the mitotic MPS1 kinase inhibitor NMS-P715.

Authors:  Roger B Slee; Brenda R Grimes; Ruchi Bansal; Jesse Gore; Corinne Blackburn; Lyndsey Brown; Rachel Gasaway; Jaesik Jeong; Jose Victorino; Keith L March; Riccardo Colombo; Brittney-Shea Herbert; Murray Korc
Journal:  Mol Cancer Ther       Date:  2013-11-26       Impact factor: 6.261

8.  Dual Inhibition of Hedgehog and c-Met Pathways for Pancreatic Cancer Treatment.

Authors:  Agnieszka A Rucki; Qian Xiao; Stephen Muth; Jianlin Chen; Xu Che; Jennifer Kleponis; Rajni Sharma; Robert A Anders; Elizabeth M Jaffee; Lei Zheng
Journal:  Mol Cancer Ther       Date:  2017-09-01       Impact factor: 6.261

9.  Inhibition of Discoidin Domain Receptor 1 Reduces Collagen-mediated Tumorigenicity in Pancreatic Ductal Adenocarcinoma.

Authors:  Kristina Y Aguilera; Huocong Huang; Wenting Du; Moriah M Hagopian; Zhen Wang; Stefan Hinz; Tae Hyun Hwang; Huamin Wang; Jason B Fleming; Diego H Castrillon; Xiaomei Ren; Ke Ding; Rolf A Brekken
Journal:  Mol Cancer Ther       Date:  2017-09-01       Impact factor: 6.261

Review 10.  Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine.

Authors:  Erik S Knudsen; Eileen M O'Reilly; Jonathan R Brody; Agnieszka K Witkiewicz
Journal:  Gastroenterology       Date:  2015-09-15       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.